Grass M, Geissler K
Wien Med Wochenschr. 2025; .
PMID: 40042734
DOI: 10.1007/s10354-025-01072-0.
Thiele J, Kvasnicka H, Gianelli U, Arber D, Tefferi A, Vannucchi A
Blood Cancer J. 2025; 15(1):31.
PMID: 40038244
PMC: 11880409.
DOI: 10.1038/s41408-025-01235-7.
Tsiara E, Makri S, Skaperda Z, Giannakoulas N, Vasilopoulos G, Kouretas D
Biomed Rep. 2025; 22(3):45.
PMID: 39882334
PMC: 11775644.
DOI: 10.3892/br.2025.1923.
Adrianzen-Herrera D, Strumlowska A
Curr Hematol Malig Rep. 2025; 20(1):6.
PMID: 39821758
DOI: 10.1007/s11899-025-00750-5.
Sazak H, Kotan M
Diagnostics (Basel). 2025; 15(1.
PMID: 39795550
PMC: 11719705.
DOI: 10.3390/diagnostics15010022.
JAK2-V617F mutation among blood donors: A meta-analysis.
Alsharif M, Mansory E, Alharazi A, Badawi M
Saudi Med J. 2024; 45(12):1289-1304.
PMID: 39658117
PMC: 11629640.
DOI: 10.15537/smj.2024.45.12.20240594.
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.
Atallah E, Deininger M
Drugs. 2024; 85(1):41-50.
PMID: 39638957
DOI: 10.1007/s40265-024-02108-2.
Models for the marrow: A comprehensive review of AI-based cell classification methods and malignancy detection in bone marrow aspirate smears.
Ghete T, Kock F, Pontones M, Pfrang D, Westphal M, Hofener H
Hemasphere. 2024; 8(12):e70048.
PMID: 39629240
PMC: 11612571.
DOI: 10.1002/hem3.70048.
Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era.
Verigou E, Chatzilygeroudi T, Lazaris V, de Lastic A, Symeonidis A
Front Oncol. 2024; 14:1447001.
PMID: 39544295
PMC: 11560873.
DOI: 10.3389/fonc.2024.1447001.
Genome sequencing in the management of myelodysplastic syndromes and related disorders.
Cazzola M, Malcovati L
Haematologica. 2024; 110(2):312-329.
PMID: 39445412
PMC: 11788631.
DOI: 10.3324/haematol.2023.284947.
Higher prevalence of poor prognostic markers at a younger age in adult patients with myelodysplastic syndrome - evaluation of a large cohort in India.
Srivastava V, Nair S, Joy M, Manipadam M, Kulkarni U, Devasia A
Mol Cytogenet. 2024; 17(1):21.
PMID: 39334460
PMC: 11438259.
DOI: 10.1186/s13039-024-00687-z.
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.
Mazzeo P, Ganster C, Wiedenhoft J, Shirneshan K, Rittscher K, Brzuszkiewicz E
Hemasphere. 2024; 8(9):e70014.
PMID: 39315323
PMC: 11417473.
DOI: 10.1002/hem3.70014.
Minimal Requirements for Cancer Initiation: A Comparative Consideration of Three Prototypes of Human Leukemia.
Hori T
Cancers (Basel). 2024; 16(17).
PMID: 39272967
PMC: 11394586.
DOI: 10.3390/cancers16173109.
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC.
Xiao W, Nardi V, Stein E, Hasserjian R
J Hematol Oncol. 2024; 17(1):56.
PMID: 39075565
PMC: 11287910.
DOI: 10.1186/s13045-024-01571-4.
The role of clonal progression leading to the development of therapy-related myeloid neoplasms.
Guarnera L, Pascale M, Hajrullaj H, Cristiano A, Mallegni F, Onorato A
Ann Hematol. 2024; 103(9):3507-3517.
PMID: 39031199
PMC: 11358309.
DOI: 10.1007/s00277-024-05803-y.
DeepDecon accurately estimates cancer cell fractions in bulk RNA-seq data.
Huang J, Du Y, Stucky A, Kelly K, Zhong J, Sun F
Patterns (N Y). 2024; 5(5):100969.
PMID: 38800361
PMC: 11117059.
DOI: 10.1016/j.patter.2024.100969.
Association of Polymorphisms in PD-1 and LAG-3 Genes with Acute Myeloid Leukemia.
Mansour L, Alqahtani M, Aljuaimlani A, Al-Tamimi J, Al-Harbi N, Alomar S
Medicina (Kaunas). 2024; 60(5).
PMID: 38792904
PMC: 11123055.
DOI: 10.3390/medicina60050721.
Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression.
Travaglini S, Marinoni M, Visconte V, Guarnera L
Biomedicines. 2024; 12(5).
PMID: 38791019
PMC: 11118122.
DOI: 10.3390/biomedicines12051054.
First Case of FLT3-Tyrosine Kinase Domain Mutant Acute Myeloid Leukemia With Unusual Onset as Isolated Bilateral Testicular Myeloid Sarcoma.
Erol V, Akgun Cagliyan G, Ufuk F, Demir D
Cureus. 2024; 16(4):e58140.
PMID: 38738062
PMC: 11088944.
DOI: 10.7759/cureus.58140.
Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
Li F, Qin T, Li B, Qu S, Pan L, Zhang P
Leukemia. 2024; 38(6):1334-1341.
PMID: 38714876
PMC: 11147759.
DOI: 10.1038/s41375-024-02262-2.